Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Neovacs

Stallergenes

Noémie Caillot

Emmanuel Nony

Philippe Moingeon

Vincent Serra

Véronique Bodo

Julien Bouley

Géraldine Grouard-vogel

Vincent Lombardi

Romain Bertrand

Eva Conde García

Laurent Reber

Pierre Bruhns

An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity

The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

Sialylated fetuin-A as a marker of immunotherapy efficacy

Growing community of inventors

Paris, France

Noémie Caillot